<p>BALB/c mice (n = 5/group) were immunized twice on day 0 and 16 with 3×10<sup>6</sup> PFU or 3×10<sup>7</sup> PFU of rBac-HA virus via intranasal route. Each group of mice was challenged by intranasal administration with 50 LD<sub>50</sub> of H5N1 influenza virus. (A) Weight loss was monitored daily for 14 days after challenge. The results were expressed in percent body weight compared to beginning of the trial. (B) Survival of all group of mice were also monitored for 14 days. *, Statistical significance with “Bac-ctrl” group (p<0.05). <i>Bac-ctrl</i>, Bac-control.</p
<p>(<b>a</b>) Schematic diagram of the immunization and challenge studies. (<b>b</b>) At 2 weeks aft...
<p>At week 5, mock vaccinated mice or mice vaccinated with vaccines (3 µg) were challenged intranasa...
<p>BALB/c mice (n = 6) were immunized on day 0 and 21 with rNP (10 µg/dose) alone or co-administered...
<p>BALB/c mice (n = 5/group) were immunized twice on day 0 and 16 with 3×10<sup>7</sup> PFU of rBac-...
<p>Each group of mice was immunized i.m. two times on days 0 and 28 with MVAtor-tri-HA or MVAtor-mon...
<p>BALB/c mice were immunized intranasally or sublingually with 1×10<sup>7</sup> PFU or 1×10<sup>8</...
<p>Groups of mice (n = 5) were intragastrically immunized three times at day 0, 14, and 28 with PBS ...
<p>At week 30 post immunization, H5N1 VLP immunized and control (PBS or 5 µg inactivated PR/8/34 H1N...
<p><b>Mice (n = 6/groups) were immunized intranasally on day 0 and 28.</b> All groups were challenge...
<p>Survival rates (A, C) and average body weight loss (B, D) of BALB/c (A, B) or C57BL/6 (C, D) mice...
<p>Female BALB/c mice (6−8 wk old, five mice per group) were intramuscularly immunized with 20 µg of...
<p>At 18 days following the last immunization, all mice in study group B were intranasally challenge...
<p>Groups of 10 BALB/c mice were either mock treated (A) or vaccinated with γ−A/PR8 (B). Mice were c...
<p>The immunized mice were intranasally challenged with the reassortant RG2 (clade 2.1) or NIBRG23 (...
<p>At day 42, vaccinated mice were challenged intranasally with a lethal dose (100 LD<sub>50</sub>) ...
<p>(<b>a</b>) Schematic diagram of the immunization and challenge studies. (<b>b</b>) At 2 weeks aft...
<p>At week 5, mock vaccinated mice or mice vaccinated with vaccines (3 µg) were challenged intranasa...
<p>BALB/c mice (n = 6) were immunized on day 0 and 21 with rNP (10 µg/dose) alone or co-administered...
<p>BALB/c mice (n = 5/group) were immunized twice on day 0 and 16 with 3×10<sup>7</sup> PFU of rBac-...
<p>Each group of mice was immunized i.m. two times on days 0 and 28 with MVAtor-tri-HA or MVAtor-mon...
<p>BALB/c mice were immunized intranasally or sublingually with 1×10<sup>7</sup> PFU or 1×10<sup>8</...
<p>Groups of mice (n = 5) were intragastrically immunized three times at day 0, 14, and 28 with PBS ...
<p>At week 30 post immunization, H5N1 VLP immunized and control (PBS or 5 µg inactivated PR/8/34 H1N...
<p><b>Mice (n = 6/groups) were immunized intranasally on day 0 and 28.</b> All groups were challenge...
<p>Survival rates (A, C) and average body weight loss (B, D) of BALB/c (A, B) or C57BL/6 (C, D) mice...
<p>Female BALB/c mice (6−8 wk old, five mice per group) were intramuscularly immunized with 20 µg of...
<p>At 18 days following the last immunization, all mice in study group B were intranasally challenge...
<p>Groups of 10 BALB/c mice were either mock treated (A) or vaccinated with γ−A/PR8 (B). Mice were c...
<p>The immunized mice were intranasally challenged with the reassortant RG2 (clade 2.1) or NIBRG23 (...
<p>At day 42, vaccinated mice were challenged intranasally with a lethal dose (100 LD<sub>50</sub>) ...
<p>(<b>a</b>) Schematic diagram of the immunization and challenge studies. (<b>b</b>) At 2 weeks aft...
<p>At week 5, mock vaccinated mice or mice vaccinated with vaccines (3 µg) were challenged intranasa...
<p>BALB/c mice (n = 6) were immunized on day 0 and 21 with rNP (10 µg/dose) alone or co-administered...